A Single-arm, Open-label, Multi-center Phase I Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
Latest Information Update: 25 Apr 2026
At a glance
- Drugs KSD 101 (Primary)
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological disorders; Hodgkin's disease; T-cell lymphoma
- Focus Adverse reactions
- Sponsors Kousai Bio
Most Recent Events
- 25 Apr 2026 New trial record